Jerill Thorpe

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Multiple Myeloma

Ejection Fraction

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
Tanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, Deborah M Stephens, Peter A Riedell, Jon E Arnason, Thomas J Kipps, Heidi H Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William George Wierda
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood (2021)